NB-5-MeO-MiPT NB-5-MeO-DALT Tryptamines

CAS NO: 1354631-79-0
Our products are for experimental research only
Chemical name: N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-N-(2-methoxybenzyl)propan-1-amine

Molecular formula: C22H31N3O2

Formula weight: 369.51 g/mol

CAS No: 1354631-79-0
Description Review
Description
Our products are for experimental research only

NB-5-MeO-MiPT is a synthetic hallucinogenic drug that acts as a psychoactive substance similar to LSD or psilocybin. It is a relatively new substance that is not very well known, with limited research on its effects, potential benefits, and risks.

Chemical name: N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-N-(2-methoxybenzyl)propan-1-amine

Molecular formula: C22H31N3O2

Formula weight: 369.51 g/mol

CAS No: 1354631-79-0

To analyze NB-5-MeO-MiPT, potential users can search Google for popular keywords and synonyms such as 5-MeO-MiPT, Newbie, NBOMe, psychoactive substances, NB-5-MeO-MiPT mechanism of action, NB-5-MeO-MiPT dosing information, NB-5-MeO-MiPT risks and benefits.

Health benefits of NB-5-MeO-MiPT: There is very limited research on the therapeutic effects of NB-5-MeO-MiPT, and it is not recommended for human use. However, some anecdotal evidence suggests that people who use NB-5-MeO-MiPT may experience increased empathy, enhanced creativity and an improved sense of well-being.

Potential effects: The effects of NB-5-MeO-MiPT are similar to other psychedelics such as LSD or psilocybin. Individuals who use NB-5-MeO-MiPT may experience a change in sensory perception, the distortion of time, enhanced emotional experiences, and altered states of consciousness. The effects of NB-5-MeO-MiPT can last between six to ten hours, depending on the dosage and individual tolerance.

Product mechanism: NB-5-MeO-MiPT acts on serotonin receptors in the brain, specifically the 5-HT2A receptor, which is responsible for mediating the effects of hallucinogenic drugs. When NB-5-MeO-MiPT binds to the 5-HT2A receptor, it induces a cascade of changes in the brain's chemical pathways and triggers a variety of psychoactive effects.

Safety: NB-5-MeO-MiPT is considered an experimental drug with no therapeutic role, and its use by humans is not recommended. The long-term effects of NB-5-MeO-MiPT use are unknown, and its legality is not clear in many countries.

Side effects: There is not much data available on the potential side effects of NB-5-MeO-MiPT. However, like other psychedelic drugs, NB-5-MeO-MiPT use may lead to adverse psychological side effects such as anxiety, paranoia, confusion, and delusions. Additionally, high doses of the drug can cause nausea, vomiting, and a rapid heartbeat.

Dosing information: There is no recommended dosage for NB-5-MeO-MiPT, and its use is considered experimental. It is typically available in powder or capsule form, and the dosages may vary depending on the product's source and purity. It is essential to take caution when using NB-5-MeO-MiPT and only use it under the supervision of a knowledgeable medical professional.

In summary, NB-5-MeO-MiPT is a relatively new synthetic hallucinogenic drug with limited research available. Its effects, benefits, and risks are not well documented, and its use by humans is not recommended. The long-term effects of NB-5-MeO-MiPT use are unknown, and individuals should take caution when using the substance. Additionally, NB-5-MeO-MiPT is likely illegal in many countries, and possession or distribution of this drug may result in criminal charges.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us